Real-world treatment patterns in patients initiating third-line therapy for relapsed or refractory multiple myeloma in Germany, Italy, the United Kingdom, France, and Spain.

Moritz LehneK Martin KortümKarthik RamasamyElena ZamagniTim d'EstrubéEvi ZhulekuMaya HannaSoham ShuklaMarco GhianiUlf MaywaldThomas WilkeLenka KellermannSue Perera

Published in: European journal of haematology (2023)

From 2016 to 2021, third-line regimens were mostly IMiD based. The MCR data demonstrated evolving treatment choices from 2016 to 2018 and 2019 to 2021, providing insights into uptake of novel agents and current RRMM European clinical practice.

Keyphrases

multiple myeloma
clinical practice
escherichia coli
newly diagnosed
acute lymphoblastic leukemia
combination therapy
machine learning
electronic health record
prognostic factors
replacement therapy
deep learning
data analysis